Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 150
- 主要终点
- cognitive function
研究概览
简要总结
Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Cholinesterase inhibitors, especially donepezil, are the first choice for mild and moderate AD. Sodium oligomannate (GV-971) is a marine-derived oligosaccharide. It is proposed that it can reconstitute the gut microbiota, and inhibit neuroinflammation in the brain as observed in animal models. It reduces Aβ deposition in the brain of Aβ-transgenic mice. The reduction in both Aβ deposition and neuroinflammation may synergistically contribute to the improvement of cognitive impairment and delay the progress of the disease. The State Food and Drug Administration of China (SFDA) approved it for the treatment of mild to moderate AD in 2019. Due to the different mechanism of cholinesterase inhibitor and GV-971, theoretically, they may synergistically improve cognitive function and delay disease progression. They are also used in patients with AD, but there is a lack of data on their effectiveness and safety. Therefore, the purpose of this observational study is to compare the efficacy and safety of donepezil and GV-971 monotherapy and combination therapy in patients with mild and moderate AD, which is of great significance for guiding the treatment of mild and moderate AD.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age of 50-85 years old , either sex;
- •met the diagnostic criteria for suspected AD;
- •mild to moderate AD patients, that is, patients with 11 points ≤Mini-Mental State Examination(MMSE) total score ≤26 points
- •total Hachinski ischemic scale (HIS) score ≤4 points;
- •memory loss for at least 12 months, with a tendency of progressive deterioration;
- •brain magnetic resonance imaging（MRI） scan suggesting a significant possibility of AD ;
- •no obvious physical signs during nervous system examination;
- •stable and reliable caregivers,
- •elementary school or higher education level
- •signed an informed consent form
排除标准
- •previous nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.);
- •mental illness according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition（DSM-IV), Text Revision criteria, including schizophrenia and other mental illness, bipolar disorder, and severe depression or paralysis;
- •unstable or severe heart, lung, liver, kidney, or hematopoietic diseases;
- •uncorrectable visual and auditory disorders that affected completing neuropsychological tests and scale assessments;
- •simultaneous use of cholinesterase inhibitors or memantine.
研究组 & 干预措施
Donepezil monotherapy group
Donepezil 5mg qd
干预措施: Donepezil (Drug)
GV-971 monotherapy group
GV-971 450mg bid
干预措施: GV-971 (Drug)
Donepezil combined with GV-971 group
Donepezil 5mg qd+GV-971 450mg bid
干预措施: Donepezil (Drug)
Donepezil combined with GV-971 group
Donepezil 5mg qd+GV-971 450mg bid
干预措施: GV-971 (Drug)
结局指标
主要结局
cognitive function
时间窗: baseline, week 12, week 24, week 36
the change of Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog) score from baseline at week 36
次要结局
未报告次要终点